Terms: = Sarcomas AND MYD88, Q99836, MYD88D, 4615 AND Treatment
4 results:
1. Inflammasome-related gene signatures as prognostic biomarkers in osteosarcoma.
Zhang N; Han Y; Cao H; Wang Q
J Cell Mol Med; 2024 May; 28(9):e18286. PubMed ID: 38742843
[TBL] [Abstract] [Full Text] [Related]
2. miR-199a-3p suppresses neuroinflammation by directly targeting myd88 in a mouse model of bone cancer pain.
Saadh MJ; Rashed AB; Jamal A; Castillo-Acobo RY; Kamal MA; Cotrina-Aliaga JC; Gonzáles JLA; Alothaim AS; Alhoqail WA; Ahmad F; Lakshmaiya N; Amin AH; Younus DG; Rojas GGR; Bahrami A; Akhavan-Sigari R
Life Sci; 2023 Nov; 333():122139. PubMed ID: 37783266
[TBL] [Abstract] [Full Text] [Related]
3. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists.
Yamazaki T; Hannani D; Poirier-Colame V; Ladoire S; Locher C; Sistigu A; Prada N; Adjemian S; Catani JP; Freudenberg M; Galanos C; André F; Kroemer G; Zitvogel L
Cell Death Differ; 2014 Jan; 21(1):69-78. PubMed ID: 23811849
[TBL] [Abstract] [Full Text] [Related]
4. Regulation of the MIR155 host gene in physiological and pathological processes.
Elton TS; Selemon H; Elton SM; Parinandi NL
Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
[TBL] [Abstract] [Full Text] [Related]